TransCode Therapeutics (RNAZ) Short Interest Ratio & Short Volume

Short interest is the volume of TransCode Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 743,600 shares of RNAZ short. 4.31% of TransCode Therapeutics' shares are currently sold short. Learn More on TransCode Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.31% of TransCode Therapeutics' floating shares are currently sold short.

TransCode Therapeutics saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 743,600 shares, a drop of 39.0% from the previous total of 1,220,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

TransCode Therapeutics currently has issued a total of 17,270,000 shares. Some of TransCode Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TransCode Therapeutics currently has a public float of 17,240,000 shares.

4.31% of TransCode Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to TransCode Therapeutics: Tonix Pharmaceuticals Holding Corp. (5.59%), Enlivex Therapeutics Ltd. (0.75%), Tempest Therapeutics, Inc. (11.82%), Cocrystal Pharma, Inc. (0.03%), Pieris Pharmaceuticals, Inc. (1.70%), Spruce Biosciences, Inc. (0.56%), Pulmatrix, Inc. (0.19%), Cyclo Therapeutics, Inc. (0.69%), Unity Biotechnology, Inc. (1.97%), Bullfrog AI Holdings, Inc. (4.76%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling RNAZ is an investing strategy that aims to generate trading profit from TransCode Therapeutics as its price is falling. RNAZ shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for TransCode Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RNAZ, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RNAZ, twice per month. The most recent reporting period available is October, 31 2024.